QS-21 Augments the Antibody Response to a Synthetic Peptide Vaccine Compared to Alum

[1]  C. Kensil,et al.  Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.

[2]  R. Gallo,et al.  HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[3]  F. Ruscetti,et al.  Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping , 1989, Journal of virology.

[4]  A. Goldstein,et al.  Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Sternberg,et al.  AIDS vaccine predictions , 1987, Nature.

[6]  C. Boucher,et al.  Immune response and epitope mapping of a candidate hiv‐1 p17 vaccine hgp30 , 1990, Journal of clinical laboratory analysis.

[7]  E. Sandström,et al.  HIV-1 peptides induce a proliferative response in lymphocytes from infected persons. , 1989, Journal of acquired immune deficiency syndromes.

[8]  L. Chedid,et al.  Current status of immunological adjuvants. , 1986, Annual review of immunology.

[9]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.